No HoFH definition could give Aegerion market lead with Juxtapid

There was little question the US FDA would approve Aegerion Pharmaceuticals' Juxtapid (lomitapide), a microsomal triglyceride transfer protein inhibitor intended to treat patients with homozygous familial hyperchodlesterolemia (HoFH) – with that OK coming about a week ahead of its 29 December Prescription Drug User Fee Act action date.